KR950007872A - 안정화된 약제학적 조성물 및 안정화용매 - Google Patents
안정화된 약제학적 조성물 및 안정화용매 Download PDFInfo
- Publication number
- KR950007872A KR950007872A KR1019940025248A KR19940025248A KR950007872A KR 950007872 A KR950007872 A KR 950007872A KR 1019940025248 A KR1019940025248 A KR 1019940025248A KR 19940025248 A KR19940025248 A KR 19940025248A KR 950007872 A KR950007872 A KR 950007872A
- Authority
- KR
- South Korea
- Prior art keywords
- solvent
- composition
- pharmaceutical
- acid
- castor oil
- Prior art date
Links
- 239000002904 solvent Substances 0.000 title claims abstract 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 9
- 230000000087 stabilizing effect Effects 0.000 title claims 2
- -1 carboxylate anion Chemical class 0.000 claims abstract 15
- 239000004359 castor oil Substances 0.000 claims abstract 14
- 235000019438 castor oil Nutrition 0.000 claims abstract 14
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract 14
- 239000002253 acid Substances 0.000 claims abstract 11
- 230000015556 catabolic process Effects 0.000 claims abstract 6
- 238000006731 degradation reaction Methods 0.000 claims abstract 6
- 239000000126 substance Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 21
- 238000000034 method Methods 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 10
- 235000019441 ethanol Nutrition 0.000 claims 10
- 239000007859 condensation product Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 230000000259 anti-tumor effect Effects 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 4
- 229960001278 teniposide Drugs 0.000 claims 4
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Polymers CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 150000007942 carboxylates Chemical class 0.000 claims 3
- 150000007522 mineralic acids Chemical class 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 1
- 238000003421 catalytic decomposition reaction Methods 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000007928 solubilization Effects 0.000 claims 1
- 238000005063 solubilization Methods 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
1. 청구범위에 기재된 발명이 속하는 기술분야
카르복실레이트 음이온 함량을 감소시킨 용매계
2. 발명이 해결하려고 하는 기술적 과제
약제학적 물질의 분해를 억제
3. 발명의 해결방법의 요지
폴리옥시에틸화된 피마자유를 산으로 처리 또는 알루미나와 접촉
4. 발명의 중요한 용도
안정화된 약제학적 조성물
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (42)
- 알킬렌 옥사이드의 축합생성물을 함유하고, 약제학적 물질의 분해를 실질적으로 방지하기에 충분히 낮은 카르복실레이트 음이온 함량을 갖는 용매.
- 제1항에 있어서, 용매의 카르복실레이트 음이온 함량이 mL당 카르복실레이트 음이은의 0.6×10-6g당량 미만 또는 이와 동일량인 용매.
- 제1항에 있어서, 축합생성물이 알킬렌옥사이드와 지질의 축합생성물인 용매.
- 제3항에 있어서, 축합생성물이 폴리옥시에틸화 피마자유인 용매.
- 제3항에 있어서, 용매가 폴리에톡실화 12-하이드록시 스테아린산인 용매.
- 제1항에 있어서, 용매가 추가로 알콜을 함유하는 용매.
- 제6항에 있어서, 알콜이 에탄올 및 폴리에틸렌 글리콜로 이루어진 그룹중에서 선택되는 용매.
- 하나 이상의 약제학적 화합물 : 및 이 약제학적 화합물을 분산시키거나 용해시킬 수 있고 약제학적 화합물의 촉매화 분해를 방지하기에 충분히 낮은 카르복실레이트 음이온 함량을 갖는 유효량의 가용화제를 함유하는 용매를 함유한 안정화된 조성물.
- 제8항에 있어서, 가용화제가 알킬렌옥사이드 변형지질인 조성물.
- 제8항에 있어서, 용매가 알콜과 폴리옥시에틸화 피마자유의 혼합물인 조성물.
- 제10항에 있어서, 용매가 에틸알콜과 폴리옥시에틸화 피마자유가 약 50 : 50용량비로 이루어진 혼합물인 조성물.
- 제8항에 있어서, 약제학적 화합물이 테니포시드, 파클리텍셀, 캠프토테신 및 이들의 유도체로 이루어진 그룹중에서 선택된 항종양화합물인 조성물.
- 제8항에 있어서, 약제학적 화합물이 카르복실레이트 옴이온의 존재하에서 분해에 민감한 화합물인 조성물.
- 제8항에 있어서, 용매가 용매 mL당 약 0.6×10-6g당량의 카르복실레이트 음이온 함량을 갖는 조성물.
- 제8항에 있어서, 용매가 용매 mL당 약 0.6×10-6g당량 미만 또는 이와 동일량의 카르복실레이트 음이온 항량을 유지하기에 효과적인 양의 산을 함유하는 조성물.
- 제15항에 있어서, 산이 무기산인 조성물.
- 제15항에 있어서, 산이 HCl, HBr, HI, HF, H2SO4, HNO3로 이루어진 그룹중에서 선택되는 조성물.
- 제8항에 있어서, 가용화제가 피마자유와 피마자유 1몰당 20내지 40몰의 에틸렌옥사이드의 폴리옥시에틸화 피마자유 축합생성물인 조성물.
- 제8항에 있어서, 용매가 용매 mL당 약 5.6×10-6g 내지 8.4×10-6g의 H+를 제공하는 양으로 무기산을 함유하는 조성물.
- 제8항에 있어서, 가용화제가 폴리옥시에틸화 지질, 폴리옥시에틸화 12-하이드록시 스테아린산 및 폴리에틸렌 글리콜로 이루어진 그룹중에서 선택되는 조성물.
- 폴리옥시에틸화 피마자유를 함유한 용매를 카르복실레이트 음이온 함량이 감소되도록 처리하여 항종양화합물의 촉매화 분해를 방지하기에 충분히 낮은 카르복실레이트 음이온 함량을 갖는 용매를 제조하고, 항종양화합물을 용매중에 분산시켜 안정화된 조성물을 제조하는 방법.
- 제21항에 있어서, 용매가 에탄올 및 폴리에털렌 글리콜로 이루어진 그룹중에서 선택된 알콜을 함유하는 방법.
- 제21항에 있어서, 용매가 에탄올과 폴리옥시에틸화 피마자유가 약 50 : 50용량이로 이루어진 혼합물인 방법.
- 제21항에 있어서, 항종양화합물이 테니포시드, 파클리텍셀, 캠프로테신 및 이들의 유도체로 이루어진 그룹중에서 선택되는 방법.
- 제21항에 있어서, 처리단계가 폴릭옥시에틸화 피마자유를 알루미늄 옥사이드와 접촉시켜 용매의 카르복실레이트 음이온 함량을 감소시키는 방법.
- 제21항에 있어서, 용매가 용매 mL당 약 0.6×10-6g당량 이하의 카르복실레이트 음이온 함량을 갖는 방법.
- 제21항에 있어서, 처리단계가 용매 mL당 5.6×10-6g이상의 H+을 제공하는 양으로 산을 첨가하는 방법.
- 제21항에 있어서, 처리단계가 용매 mL당 5.6×10-6내지 8.6×10-6g의 H+을 제공하는 양으로 첨가하는 방법.
- 제28항에 있어서, 산이 무기산인 방법.
- 제28항에 있어서, 산이 HCl, HBr, HF, HI, H2SO4및 HNO3로 이루어진 그룹중에서 선택되는 조성물인 방법.
- 카르복실레이트 음이온의 존재하에 분해될 수 있는 하나이상의 약제학적 물질과 알킬렌옥사이드의 축합생성물을 함유하는 약제학적 조성물을 정제하여 카르복실레이트 음이온 함량을 약제학적 물질의 촉매화 분해를 실질적으로 방지하기에 충분한 양으로 감소시켜, 언급된 약제학적 조성물을 안정화하는 방법.
- 제31항에 있어서, 약제학적 조성물이 에탄올과 폴리옥시에틸화 피마자유를 약 50 : 50용적의 양으로 함유하는 방법.
- 제31항에 있어서, 약제학적 물질이 파클리텍셀, 테니포시드. 캠프토테신 및 이들의 유도체로 이루어진 그룹중에서 선택되는 방법.
- 제32항에 있어서, 정제단계가 산을 폴리옥시에틸화 피마자유에 카르복실화 음이온의 양을 감소시켜 약제학적 물질의 분해를 방지하는 양으로 첨가하는 방법.
- 제34항에 있어서, 산이 약제학적 조성물 mL당 5.6×10-6g 내지 8.4×10-6g의 H+을 제공하는 양으로 첨가되는 방법.
- 제34항에 있어서, 정제단계가 카르복실레이트 음이온 함량을 약제학적 조성물 mL당 0.6×10-6g당량 미만으로 낮쳐주는 방법.
- 에탄올과 용해량의 가용화제 하나이상을 함유한 용매를 처리하여 카르복실레이트 음이온 함량을 파크릴텍셀, 테니포시드, 캠프토테신 및 이들의 유도체로 이루어진 그룹중에서 선택된 약제학적 물질의 분해를 실질적으로 방지하기에 충분히 낮은 수준으로 감소시켜, 언급된 약제학적 물질과 용매를 함유한 약제학적 조성물을 안정화시키는 방법.
- 제37항에 있어서, 가용화재가 폴리옥시에틸화 지질, 폴리에톡실화 12-하이드록시 스테아린산 및 폴리에틸렌 글리콜로 이루어진 그룹중에서 선택되는 방법.
- 제37항에 있어서, 가용화제가 폴리옥시에틸화 피마자유인 방법.
- 제37항에 있어서, 폴리옥시에틸화 피마자유가 피마자유와 피마자유 1몰당 약 20 내지 40몰의 에틸렌옥사이드의 축합생성물인 방법.
- 제37항에 있어서, 처리단계가 용매를 산과 혼합함을 포함하고, 산이 약제학적 조성몰 mL당 5.6×10-6내피 8.4×10-6g의 H+을 제공하는 양인 방법.
- 제38항에 있어서, 처리단계가 용매를 알루미늄 옥사이드와 접촉시켜 카르복실레이트 함량을 감소시켜 약제학적 물질의 분해를 방지하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12802693A | 1993-09-29 | 1993-09-29 | |
US08/128.026 | 1993-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950007872A true KR950007872A (ko) | 1995-04-15 |
KR100515631B1 KR100515631B1 (ko) | 2005-12-08 |
Family
ID=22433231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940025248A KR100515631B1 (ko) | 1993-09-29 | 1994-09-29 | 안정화된약제학적조성물및안정화용매 |
Country Status (28)
Country | Link |
---|---|
US (1) | US5504102A (ko) |
EP (1) | EP0645145B1 (ko) |
JP (1) | JP3447386B2 (ko) |
KR (1) | KR100515631B1 (ko) |
CN (1) | CN1140297C (ko) |
AT (1) | ATE149843T1 (ko) |
AU (1) | AU686651B2 (ko) |
BE (1) | BE1007987A5 (ko) |
BR (1) | BR1100361A (ko) |
CA (1) | CA2132936C (ko) |
CY (1) | CY2035A (ko) |
CZ (2) | CZ287358B6 (ko) |
DE (1) | DE69402022T2 (ko) |
DK (1) | DK0645145T3 (ko) |
ES (2) | ES2098842T3 (ko) |
FI (1) | FI115825B (ko) |
GR (1) | GR3023583T3 (ko) |
HK (1) | HK96797A (ko) |
HU (1) | HU217962B (ko) |
IL (1) | IL111065A (ko) |
IT (1) | IT1279383B1 (ko) |
NO (1) | NO308447B1 (ko) |
NZ (1) | NZ264526A (ko) |
PL (1) | PL176826B1 (ko) |
RU (1) | RU2107500C1 (ko) |
SG (1) | SG50479A1 (ko) |
TW (1) | TW406020B (ko) |
ZA (1) | ZA947482B (ko) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69320206T2 (de) * | 1992-11-27 | 1999-02-11 | Napro Biotherapeutics Inc | Paclitaxel enthaltende injizierbare zusammensetzung |
US20030068362A1 (en) * | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
US6335356B1 (en) | 1994-01-07 | 2002-01-01 | Sugen, Inc. | Method of treating a patient by parenteral administration of a lipophilic compound |
US5631287A (en) * | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
NL9500340A (nl) * | 1995-02-22 | 1996-10-01 | Yew Tree Pharmaceuticals B V | Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat. |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
DE19536165A1 (de) * | 1995-09-28 | 1997-04-03 | Basf Ag | Verfahren zur Reinigung von alkoxylierten Fetten |
US6964946B1 (en) | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
CN1209059A (zh) * | 1995-12-21 | 1999-02-24 | 基因实验室技术有限公司 | 紫杉烷类组合物及方法 |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
KR100358934B1 (ko) * | 1996-09-13 | 2003-01-29 | 주식회사한국신약 | 탁솔을함유한주사용약제조성물 |
EP0954283B1 (en) | 1996-12-30 | 2007-03-21 | Battelle Memorial Institute | Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
BE1011216A3 (fr) * | 1997-06-13 | 1999-06-01 | Thissen En Abrege L T B Lab | Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition. |
US5925776A (en) * | 1997-12-24 | 1999-07-20 | Schein Pharmacetical, Inc. | Polyethoxylated castor oil, process of making the same and formulations thereof |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
WO2000023070A1 (en) * | 1998-10-20 | 2000-04-27 | Ben Venue Laboratories, Inc. | Process for purification of solvents useful in the preparation of pharmaceutical compositions |
US6017948A (en) * | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US6071952A (en) * | 1998-12-02 | 2000-06-06 | Mylan Pharmaceuticals, Inc. | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
US6828346B2 (en) * | 1999-10-25 | 2004-12-07 | Supergen, Inc. | Methods for administration of paclitaxel |
US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
WO2001072300A1 (en) * | 2000-03-24 | 2001-10-04 | Baker Norton Pharmaceuticals, Inc. | Uses of metal salts to stabilize taxane-based compositions |
WO2001076559A1 (en) | 2000-04-10 | 2001-10-18 | Teva Pharmaceutical Industries Ltd. | Method 0f administration of paclitaxel-plasma protein formulation |
EP1280557B1 (en) | 2000-05-12 | 2012-06-20 | Samyang Corporation | Method for the preparation of polymeric micelle via phase separation of block copolymer |
US7217770B2 (en) | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
WO2002009695A1 (en) * | 2000-08-02 | 2002-02-07 | Atossa Healthcare, Inc. | Bimodal emulsions of taxanes and butyrate polyalcohol esters |
US6410059B1 (en) * | 2000-10-20 | 2002-06-25 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing cow urine distillate and an antibiotic |
PL203300B1 (pl) | 2000-10-31 | 2009-09-30 | Akad Medyczna | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego |
ATE413164T1 (de) | 2000-11-09 | 2008-11-15 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
WO2002043765A2 (en) * | 2000-11-28 | 2002-06-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
ATE414511T1 (de) | 2000-12-05 | 2008-12-15 | Los Angeles Childrens Hospital | Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung |
US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
PL207720B1 (pl) * | 2001-01-25 | 2011-01-31 | Bristol Myers Squibb Co | Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej |
WO2002076402A2 (en) | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty amine drug conjugates |
AU2002305099A1 (en) * | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty alcohol drug conjugates |
DE10115740A1 (de) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
EP1379231A2 (en) | 2001-04-06 | 2004-01-14 | Cytorex Biosciences, Inc. | Pharmacologically active strong acid solutions |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
KR100774366B1 (ko) | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
KR20030023369A (ko) * | 2001-09-13 | 2003-03-19 | 한국과학기술연구원 | 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법 |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
EP1461056A4 (en) * | 2001-11-26 | 2006-01-25 | Supergen Inc | PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS |
AU2002357012A1 (en) * | 2001-11-27 | 2003-06-10 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
DE60309300T3 (de) * | 2002-03-20 | 2011-02-24 | Elan Pharma International Ltd. | Nanopartikelzusammensetzungen von angiogeneseinhibitoren |
CZ294371B6 (cs) * | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
AU2003247671B2 (en) * | 2002-07-15 | 2008-02-14 | Alcon, Inc. | Bioerodible film for ophthalmic drug delivery |
US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
AU2003296897A1 (en) * | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
EP1560577A2 (en) * | 2002-11-08 | 2005-08-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
EP1558241A2 (en) * | 2002-11-08 | 2005-08-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using taxane derivatives |
ATE437654T1 (de) * | 2003-05-19 | 2009-08-15 | Ebewe Pharma Gmbh Nfg Kg | Verfahren zur herstellung einer stabilen injizierbaren formulierung von paclitaxel |
RU2236852C1 (ru) * | 2003-06-23 | 2004-09-27 | Закрытое акционерное общество "ДЕСКО" | Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций |
US20050016926A1 (en) * | 2003-07-24 | 2005-01-27 | Dabur Research Foundation | Stabilized formulation |
EP1648988A1 (en) * | 2003-07-24 | 2006-04-26 | Dabur Research Foundation | Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations |
US7311901B2 (en) | 2003-10-10 | 2007-12-25 | Samyang Corporation | Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
EP1947094A3 (en) | 2003-12-12 | 2009-02-18 | Quiral Quimica Do Brasil | Process for the preparation of taxane derivatives |
CN1893892B (zh) * | 2003-12-17 | 2012-03-28 | 比奥纽默里克药物公司 | 喜树碱的药物制剂和制备它们的方法 |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
US7361683B2 (en) * | 2004-11-24 | 2008-04-22 | Yung Shin Pharm. Ind., Co., Ltd | Paclitaxel aqueous injection solution and methods for preparing the same |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
WO2008105852A2 (en) * | 2006-10-26 | 2008-09-04 | Creighton University | Mucoadhesive nanoparticles for cancer treatment |
US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
DK2254570T3 (da) * | 2008-02-20 | 2014-02-03 | Actelion Pharmaceuticals Ltd | Kombination omfattende paclitaxel til behandling af ovariecancer |
DE102008059201A1 (de) * | 2008-11-27 | 2010-06-02 | GÖPFERICH, Achim, Prof. Dr. | In situ präzipitierende Arzneistofflösungen |
EP2204167A1 (en) | 2009-01-05 | 2010-07-07 | Azad Pharma AG | Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules |
HUE033312T2 (en) | 2009-07-20 | 2017-11-28 | Bristol Myers Squibb Co | Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases |
AR093275A1 (es) | 2010-03-17 | 2015-05-27 | Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos |
US9345683B2 (en) * | 2010-11-08 | 2016-05-24 | Cadila Pharmaceuticals Limited | Pharmaceutical composition of taxoids |
US9198969B2 (en) * | 2012-08-15 | 2015-12-01 | Yung Shin Pharm. Ind. Co., Ltd. | Stable pharmaceutical formulation of cabazitaxel |
SG11201506116XA (en) * | 2013-02-05 | 2015-09-29 | 1Globe Health Inst Llc | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
EP2777691A1 (en) | 2013-03-14 | 2014-09-17 | Pharmachemie B.V. | Taxoid - Purification of Liquid Excipients |
US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
AR100034A1 (es) | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR830002614B1 (ko) * | 1980-04-14 | 1983-05-30 | 후로인도 산교오 가부시끼 가이샤 | 활성화된 의약조성물의 제법 |
JPS61152621A (ja) * | 1984-12-27 | 1986-07-11 | Lion Corp | 液状透明口腔用組成物 |
RO92831B1 (ro) * | 1985-07-29 | 1988-01-01 | Viorica Dobrescu | Procedeu de purificare a polietilenglicolilor |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
JPH02196789A (ja) * | 1989-01-25 | 1990-08-03 | Sankyo Co Ltd | リゾキシン類化合物の安定化法 |
JP2598206B2 (ja) * | 1992-07-17 | 1997-04-09 | ツヤック株式会社 | 蛋白繊維品のハイグラル・エクスパンションの安定化法 |
DE69320206T2 (de) * | 1992-11-27 | 1999-02-11 | Napro Biotherapeutics Inc | Paclitaxel enthaltende injizierbare zusammensetzung |
AU5553894A (en) * | 1992-11-27 | 1994-06-22 | F.H. Faulding & Co. Limited | Injectable taxol composition |
-
1994
- 1994-08-25 TW TW083107808A patent/TW406020B/zh active
- 1994-09-23 NZ NZ264526A patent/NZ264526A/en not_active IP Right Cessation
- 1994-09-26 CZ CZ19942349A patent/CZ287358B6/cs not_active IP Right Cessation
- 1994-09-26 FI FI944448A patent/FI115825B/fi active IP Right Grant
- 1994-09-26 ZA ZA947482A patent/ZA947482B/xx unknown
- 1994-09-26 CA CA002132936A patent/CA2132936C/en not_active Expired - Fee Related
- 1994-09-26 IL IL11106594A patent/IL111065A/xx not_active IP Right Cessation
- 1994-09-27 HU HU9402776A patent/HU217962B/hu not_active IP Right Cessation
- 1994-09-27 NO NO943583A patent/NO308447B1/no not_active IP Right Cessation
- 1994-09-27 JP JP23011894A patent/JP3447386B2/ja not_active Expired - Lifetime
- 1994-09-27 SG SG1996002365A patent/SG50479A1/en unknown
- 1994-09-27 DE DE69402022T patent/DE69402022T2/de not_active Expired - Fee Related
- 1994-09-27 EP EP94115180A patent/EP0645145B1/en not_active Expired - Lifetime
- 1994-09-27 ES ES94115180T patent/ES2098842T3/es not_active Expired - Lifetime
- 1994-09-27 DK DK94115180.5T patent/DK0645145T3/da active
- 1994-09-27 AT AT94115180T patent/ATE149843T1/de not_active IP Right Cessation
- 1994-09-28 BE BE9400879A patent/BE1007987A5/fr not_active IP Right Cessation
- 1994-09-28 CN CNB941165809A patent/CN1140297C/zh not_active Expired - Fee Related
- 1994-09-28 AU AU74273/94A patent/AU686651B2/en not_active Ceased
- 1994-09-28 RU RU94037231A patent/RU2107500C1/ru not_active IP Right Cessation
- 1994-09-28 IT IT94RM000621A patent/IT1279383B1/it active IP Right Grant
- 1994-09-29 PL PL94305240A patent/PL176826B1/pl not_active IP Right Cessation
- 1994-09-29 ES ES09402047A patent/ES2095802A1/es not_active Withdrawn
- 1994-09-29 KR KR1019940025248A patent/KR100515631B1/ko not_active IP Right Cessation
-
1995
- 1995-01-18 US US08/374,093 patent/US5504102A/en not_active Expired - Fee Related
-
1997
- 1997-04-28 BR BR1100361-8A patent/BR1100361A/pt active IP Right Grant
- 1997-05-29 GR GR970401231T patent/GR3023583T3/el unknown
- 1997-06-26 HK HK96797A patent/HK96797A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY203598A patent/CY2035A/xx unknown
- 1998-06-23 CZ CZ19981998A patent/CZ287485B6/cs not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950007872A (ko) | 안정화된 약제학적 조성물 및 안정화용매 | |
AU771577B2 (en) | Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents | |
KR100330316B1 (ko) | 탁산유도체를기재로한주사용조성물 | |
KR960028918A (ko) | 국소용 약제학적 조성물 | |
BR0206511A (pt) | Formulação parenteral para análogos de epotilona | |
KR950703932A (ko) | 안정화된 의학용 에어로졸 용액 제제(Stabilized medicinal aerosol solution formulations) | |
IL151311A0 (en) | Pharmaceutical compositions containing propofol | |
US7699987B2 (en) | Stabilized formulation | |
JP3199475B2 (ja) | ビタミンa類可溶化水溶液の安定化法 | |
KR930702965A (ko) | 생체이용성이 개선된 프로부콜 함유 제약 조성물 | |
IE873348L (en) | Compositions for topical application | |
AU2003256786B2 (en) | Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations | |
Whitworth et al. | Stability of aspirin in liquid and semisolid bases IV: Polyethylene glycol 400 diacetate and triethylene glycol diacetate | |
Ghosh et al. | Product development studies for the selection of an ideal solvent system for diazepam in injectable formulations | |
NL9500340A (nl) | Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080825 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |